← Leaderboards
Clark E Tedford
Solentix Biosciences, Inc.
$7,345,430
Attributed
$7,523,884
Total exposure
9
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.9M · FY2005–23$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$7,523,884 · 9
By mechanism
R44$6,293,037 · 3
R43$1,230,847 · 6
Top collaborators
- Janis T Eells2 shared
Others in their field
Top investigators on “Blindness”
- Randall J Bateman · Washington University$137,189,188
- John M Lachin · George Washington University$122,970,601
- David M Nathan · Massachusetts Institute Of Technology$118,921,924
- Beth Baseler · Leidos Biomedical Research, Inc.$111,479,515
- Judith S Hochman · New York University School Of Medicine$100,149,457
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$96,562,493
Research focus
BlindnessSmall Business Innovation Research GrantMedicineVisual AcuityMitochondriaPhotobiomodulationMetabolicAreaProspectiveContrast SensitivityApplications GrantsRestorative TreatmentBaseMedicalMedical DevicePreventiveAge RelatedDrusenDesignDisease ProgressionResourcesInflammationInstrumentMasks
Grant awards (16)
LIGHTSITE IIIB: Clinical Evaluation of Photobiomodulation (PBM) in dry AMD Patients$1,169,339
R44 · FY2023 · EY · contact PI
The Use of Photobiomodulation (PBM) in the Treatment for Diabetic Macular Edema$239,680
R44 · FY2022 · EY · contact PI
The Use of Photobiomodulation (PBM) in the Treatment for Diabetic Macular Edema$674,742
R44 · FY2021 · EY · contact PI
Clinical Evaluation of Photobiomodulation (PBM) in dry AMD Patients$1,025,600
R44 · FY2020 · EY · contact PI
The Use of Photobiomodulation (PBM) in the Treatment for Diabetic Macular Edema$897,302
R44 · FY2020 · EY · contact PI
Clinical Evaluation of Photobiomodulation (PBM) in dry AMD Patients$1,502,600
R44 · FY2019 · EY · contact PI
A pilot clinical study to evaluate the use of photobiomodulation in patients with dry age-related macular degeneration$140,000
R43 · FY2017 · EY · contact PI
The Development of Photobiomodulation for the Treatment of Dry Age-related Macular Degeneration$89,685
R43 · FY2017 · EY · contact PI
The Development of Photobiomodulation for the Treatment of Dry Age-related Macular Degeneration$267,223
R43 · FY2015 · EY · contact PI
A pilot clinical study to evaluate the use of photobiomodulation in patients with dry age-related macular degeneration$256,010
R43 · FY2015 · EY · contact PI
MASP-2 Therapy for Macular Degeneration$142,140
R43 · FY2007 · EY · contact PI
Novel 5-HT treatments for METH post-addiction therapy$358,143
R44 · FY2006 · DA · contact PI
Novel 5-HT treatments for METH post-addiction therapy$425,631
R44 · FY2005 · DA
MASP-2 MoAB therapeutics for MI/RP injury$127,000
R43 · FY2005 · HL
Novel DA D1 treatments for METH post-addiction therapy$108,789
R43 · FY2003 · DA
Novel 5-HT treatments for METH post-addiction therapy$100,000
R43 · FY2003 · DA